BONINE FASTER-ACTING- diphenhydramine hcl tablet
WellSpring Pharmaceutical Corporation

Disclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they comply with applicable regulations and policies. FDA has not evaluated whether this product complies.

BONINE®
MECLIZINE HYDROCHLORIDE • ANTIEMETIC

Active ingredient (in each tablet)

Diphenhydramine HCl 25 mg

Purpose

Antiemetic

Uses

for prevention and treatment of nausea, vomiting, Uses or dizziness associated with motion sickness

Warnings

Do not use

■ for children under 6 years of age unless

■ Do not use with any other product containing diphenhydramine, including one used on skin

Ask a doctor before use if you have

■ difficulty in urination due to enlargement of the prostate gland

■ glaucoma

■ difficulty in urination due to enlargement of the prostate gland

Ask a doctor or pharmacist before use if you are

taking sedatives or tranquilizers.

When using this product

■ marked drowsiness may occur

■ alcohol, sedatives, and tranquilizers may increase drowsiness

■ avoid alcoholic beverages

■ use caution when driving a motor vehicle or operating machinery

If pregnant or breast-feeding

ask a health professional before use.

Keep out of reach of children

In case of overdose, get medical help or contact a Poison Control Center right away.

Directions

■ dosage should be taken 30 minutes before you begin motion activity.

■ adults and children 12 years and over: take 1 to 2 tablets with Water every 4 to 6 hours, not to exceed 12 tablets (300 milligrams) in 24 hours, or as directed by a doctor.

■ Children 6 to under 12 years of age: take 1 tablet with Water every 4 to 6 hours, not to exceed 6 tablets (150 milligrams) in 24 hours, or as directed by a doctor.

Other information

■ Each tablet contains: Calcium 60mg

■ Store at 25°C (77°F); excursions permitted between 15° - 30°C (59° - 86°F)

■ protect from moisture

■ see end flap for expiration date and lot number

Inactive ingredients

Croscarmellose sodium, dibasic calcium phosphate dihydrate, FD&C blue #1, aluminum lake, magnesium stearate, microcrystalline cellulose, silicone dioxide, stearic acid

Questions?

1-844-241-5454 or www.bonine.com

TAMPER EVIDENT: DO NOT USE IF OUTER PACKAGE IS OPENED OR BLISTER IS TORN OR BROKEN. Keep Carton for important drug facts information.

Distributed by: WellSpring
Pharmaceutical Corporation
Sarasota, FL 34243

Money Back Guarantee

PRINCIPAL DISPLAY PANEL 65197-616-16

NEW

9X the Adventure**

Diphenhydramine HCl - Antiemetic 25 mg

Prevents & Treats:

Vomiting • Nausea • Dizziness • Motion Sickness

*See back panel reference

* Than Meclizine HCL 25 mg per onset of action from The U.S. National Library of Medicine (NLM)

** Results may vary

FASTER-ACTING* RELIEF

TAKE WITH WATER

Bonine Faster Acting 2.0

BONINE FASTER-ACTING

diphenhydramine hcl tablet

Product Information			
Product Type	HUMAN OTC DRUG	**Item Code (Source)**	NDC:65197-616
Route of Administration	ORAL		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
DIPHENHYDRAMINE HYDROCHLORIDE (UNII: TC2D6JAD40) (DIPHENHYDRAMINE - UNII:8GTS82S83M)	DIPHENHYDRAMINE HYDROCHLORIDE	25 mg

Inactive Ingredients

Ingredient Name	Strength
CROSCARMELLOSE SODIUM (UNII: M28OL1HH48)	
DIBASIC CALCIUM PHOSPHATE DIHYDRATE (UNII: O7TSZ97GEP)	
FD&C BLUE NO. 1 ALUMINUM LAKE (UNII: J9EQA3S2JM)	
MAGNESIUM STEARATE (UNII: 70097M6I30)	
MICROCRYSTALLINE CELLULOSE 101 (UNII: 7T9FYH5QMK)	
SILICON DIOXIDE (UNII: ETJ7Z6XBU4)	
STEARIC ACID (UNII: 4ELV7Z65AP)	

Product Characteristics

Color	blue	**Score**	no score
Shape	ROUND	**Size**	9mm
Flavor		**Imprint Code**	WS1
Contains			

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:65197-616-16	2 in 1 BOX	05/01/2023	
1		8 in 1 BLISTER PACK; Type 0: Not a Combination Product		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
OTC monograph final	part336	05/01/2023	

Labeler - WellSpring Pharmaceutical Corporation (110999054)

Revised: 7/2022 WellSpring Pharmaceutical Corporation